Menu
Search
|

Menu

Close
X

Spero Therapeutics Inc SPRO.OQ (NASDAQ Stock Exchange Global Select Market)

9.98 USD
-- (--)
As of Feb 22
chart
Previous Close 9.98
Open --
Volume --
3m Avg Volume --
Today’s High --
Today’s Low --
52 Week High 15.39
52 Week Low 9.66
Shares Outstanding (mil) --
Market Capitalization (mil) --
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.80 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
1
FY16
0
EPS (USD)
FY17
-0.869
FY16
-1.133
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
--
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

Milind Deshpande
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Ankit Mahadevia
President, Chief Executive Officer, Director, Since 2015
Salary: $360,500.00
Bonus: $108,150.00
Joel Sendek
Chief Financial Officer, Since 2017
Salary: --
Bonus: --
Cristina Larkin
Chief Operating Officer and Chief Commercial Officer, Since 2017
Salary: --
Bonus: --
Timothy Keutzer
Senior Vice President - Development, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

675 Massachusetts Ave Ste 14
CAMBRIDGE   MA   02139-3309

Phone: +1857.2421600

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, developing and commercializing novel treatments for MDR bacterial infections. The Company is developing a portfolio of novel product candidates, including SPR994, Potentiator Platform (SPR741 and SPR206), and SPR720. SPR994 is novel oral formulation of tebipenem, a carbapenem-class antibiotic. SPR994 is effective against a broad spectrum of MDR bacterial infections, its initial focus is on the treatment of cUTIs. Potentiator platform that enables to develop drugs that expand the spectrum and potency of existing antibiotics, including inactive antibiotics, against Gram-negative bacteria. SPR720 is novel oral therapy product candidate designed for the treatment of NTM, a rare lung infection often occurring in patients with compromised immune systems, including HIV, or respiratory conditions, such as cystic fibrosis, asthma and bronchiectasis.

SPONSORED STORIES